Overweight Clinical Trial
Official title:
Cardiometabolic Effects of Increasing Non-Exercise Physical Activity Combined With Aerobic Exercise in Overweight Young Women
Verified date | March 2024 |
Source | Kastamonu University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to investigate whether increasing non-exercise physical activity combined with aerobic exercise in overweight young women is superior to performing aerobic exercise alone in terms of some cardiometabolic variables. The main question it aims to answer is: • Do both increasing non-exercise physical activity and doing aerobic exercise add more beneficial cardiometabolic effects to performing aerobic exercise alone in overweight young women? To answer this question, overweight young women will be randomly assigned to two different groups of this research. Volunteers in one of the groups will do moderate-intensity aerobic training and the other group will increase their non-exercise physical activities in addition to moderate-intensity aerobic training. Then researchers will compare two groups to see the differences in cardiometabolic variables.
Status | Active, not recruiting |
Enrollment | 32 |
Est. completion date | June 1, 2025 |
Est. primary completion date | March 18, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - To have a body mass index between 25 kg.(m2)-1 and 29.9 kg.(m2)-1 - Self reported sitting time greater than 7 hours per day - Not exercising regularly in the last 3 months Exclusion Criteria: - Hypertension - Coronary heart disease - Heart failure - Diabetes mellitus (A1C being 6.5% and above) - Prediabetes (A1C between 5.7% and 6.4%) - Metabolic syndrome - Hypothyroidism - Non-alcoholic fatty liver disease - Chronic inflammatory disease - Chronic renal failure - Cushing's syndrome - Musculoskeletal disorder that will affect the ability to do physical activity - HIV infection - Being on antihypertensive medication - Being on lipid-lowering medication - Being on antidiabetic medication - Being on systemic glucocorticoid medication - Smoking - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Turkey | Kastamonu University, Çatalzeytin Vocational School | Çatalzeyti?n | Kastamonu |
Lead Sponsor | Collaborator |
---|---|
Kastamonu University |
Turkey,
Kozey Keadle S, Lyden K, Staudenmayer J, Hickey A, Viskochil R, Braun B, Freedson PS. The independent and combined effects of exercise training and reducing sedentary behavior on cardiometabolic risk factors. Appl Physiol Nutr Metab. 2014 Jul;39(7):770-80. doi: 10.1139/apnm-2013-0379. Epub 2014 Jan 7. — View Citation
Kozey-Keadle S, Libertine A, Staudenmayer J, Freedson P. The Feasibility of Reducing and Measuring Sedentary Time among Overweight, Non-Exercising Office Workers. J Obes. 2012;2012:282303. doi: 10.1155/2012/282303. Epub 2011 Nov 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Low Density Lipoprotein (LDL) Cholesterol | Fasting blood samples will be taken by applying a vacutainer needle to the appropriate vein following a 12-hour fast and will be analyzed immediately in the biochemistry laboratory. | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Primary | High Density Lipoprotein (HDL) Cholesterol | Fasting blood samples will be taken by applying a vacutainer needle to the appropriate vein following a 12-hour fast and will be analyzed immediately in the biochemistry laboratory. | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Primary | Total Cholesterol | Fasting blood samples will be taken by applying a vacutainer needle to the appropriate vein following a 12-hour fast and will be analyzed immediately in the biochemistry laboratory. | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Primary | Glycated Hemoglobin (HbA1C) | Fasting blood samples will be taken by applying a vacutainer needle to the appropriate vein following a 12-hour fast and will be analyzed immediately in the biochemistry laboratory. | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Primary | Serum Triglycerides | Fasting blood samples will be taken by applying a vacutainer needle to the appropriate vein following a 12-hour fast and will be analyzed immediately in the biochemistry laboratory. | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Primary | Maximal Oxygen Consumption | Maximal oxygen consumption will be estimated by the Rockport 1 Mile Walk Test | The week before the beginning of the interventions, and the week after the interventions | |
Primary | Systolic Blood Pressure | Measurements will be made on the arm with a digital blood pressure monitor after resting for at least 10 minutes in a supine position to ensure hemodynamic stability. By wrapping the cuff around the arm, brachial systolic blood pressure will be automatically measured. | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Primary | Diastolic Blood Pressure | Measurements will be made on the arm with a digital blood pressure monitor after resting for at least 10 minutes in a supine position to ensure hemodynamic stability. By wrapping the cuff around the arm, brachial diastolic blood pressure will be automatically measured. | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Secondary | Body Fat Percentage | Body fat percentage will be measured by bioelectrical impedance analysis | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Secondary | Fat-free Mass | Fat-free mass will be measured by bioelectrical impedance analysis | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Secondary | Waist Circumference | Waist circumference will be measured in centimeters in the horizontal plane with a tape measure from the narrowest part of the waist area, with feet together, immediately after normal expiration without holding the breath. | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions | |
Secondary | Hip Circumference | Hip circumference will be measured in centimeters in the horizontal plane with a tape measure from the widest part of the hip. | The week before the beginning of the interventions, at 4th week of the intervention , and the week after the interventions |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
Completed |
NCT02899390 -
Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 |